AIM
PBYI icon

Alambic Investment Management’s Puma Biotechnology PBYI Stock Holding History

Alambic Investment Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-5,400
Closed -$201K – 655
2017
Q1 		$201K Buy
+5,400
New +$197K 0.02% 575

Other funds holding PBYI

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Alambic Investment Management's PBYI Position: Q2 2017 in Review

Alambic Investment Management sold out of Puma Biotechnology (PBYI) in Q2 2017, closing a stake of 5,400 shares — an estimated $201K sold.

Alambic Investment Management first reported a position in PBYI in Q1 2017 and held it in 1 quarter. The position peaked at $201K in Q1 2017. 154 funds tracked by Wall St. Rank hold PBYI as of Q2 2017.

  • Alambic Investment Management reported no remaining Puma Biotechnology position as of Q2 2017 after selling out during the quarter.
  • Alambic Investment Management sold 5,400 Puma Biotechnology shares in Q2 2017, an estimated $201K.
  • Alambic Investment Management first reported a position in Puma Biotechnology in Q1 2017 and held it in 1 quarter.
  • Alambic Investment Management's Puma Biotechnology position peaked at $201K in Q1 2017.
  • 154 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2017.

Based on Alambic Investment Management's 13F filing for Q2 2017, filed 14 Aug 2017.